Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells

Enzalutamide is a second-generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, AR dysfunction means that resistance to enzalutamide will eventually develop. Thus, novel agents are urgently needed to treat this devastating disease. Triptolide (TPL), a key active compound extracted from the Chinese herb Thunder God Vine (Tripterygium wilfordii Hook F.), possesses anti-cancer activity in human prostate cancer cells. However, the effects of TPL against CRPC cells and the underlying mechanism of any such effect are unknown. In this study, we found that TPL at low dose inhibits the transactivation activity of both full-length and truncated AR without changing their protein levels. Interestingly, TPL inhibits phosphorylation of AR and its CRPC-associated variant AR-V7 at Ser515 through XPB/CDK7. As a result, TPL suppresses the binding of AR to promoter regions in AR target genes along with reduced TFIIH and RNA Pol II recruitment. Moreover, TPL at low dose reduces the viability of prostate cancer cells expressing AR or AR-Vs. Low-dose TPL also shows a synergistic effect with enzalutamide to inhibit CRPC cell survival in vitro, and enhances the anti-cancer effect of enzalutamide on CRPC xenografts with minimal side effects. Taken together, our data demonstrate that TPL targets the transactivation activity of both full-length and truncated ARs. Our results also suggest that TPL is a potential drug for CRPC, and can be used in combination with enzalutamide to treat CRPC.

[1]  P. Houghton,et al.  The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. , 2007, Methods.

[2]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[3]  Yuan Yang,et al.  Triptolide Inhibits the Proliferation of Prostate Cancer Cells and Down-Regulates SUMO-Specific Protease 1 Expression , 2012, PloS one.

[4]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[5]  J. Schalken,et al.  Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation. , 2015, The Journal of urology.

[6]  S. von Felten,et al.  Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. , 2016, European journal of cancer.

[7]  D. Tindall,et al.  Alternatively spliced androgen receptor variants. , 2011, Endocrine-related cancer.

[8]  C. Drake,et al.  Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy , 2014, Oncogene.

[9]  R. Andersen,et al.  An androgen receptor N-terminal domain antagonist for treating prostate cancer. , 2013, The Journal of clinical investigation.

[10]  Hui Zhang,et al.  Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker , 2012, Tumor Biology.

[11]  G. Georg,et al.  A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer , 2012, Science Translational Medicine.

[12]  Qiuyan Liu.  Triptolide and its expanding multiple pharmacological functions. , 2011, International immunopharmacology.

[13]  G. Capranico,et al.  Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. , 2012, Cancer research.

[14]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[15]  Howard C. Shen,et al.  Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor , 2014, Clinical Cancer Research.

[16]  Jun O. Liu,et al.  Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation. , 2016, Angewandte Chemie.

[17]  T. Corson,et al.  Triptolide Directly Inhibits dCTP Pyrophosphatase , 2011, Chembiochem : a European journal of chemical biology.

[18]  P. Purushottamachar,et al.  Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo , 2015, Oncotarget.

[19]  Jun O. Liu,et al.  XPB, a subunit of TFIIH, is a target of the natural product triptolide. , 2011, Nature chemical biology.

[20]  Chawnshang Chang,et al.  From Androgen Receptor to the General Transcription Factor TFIIH , 2000, The Journal of Biological Chemistry.

[21]  R. Sellers,et al.  Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Johan Lindberg,et al.  The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7 , 2015, Scientific Reports.

[23]  Pingping Shen,et al.  TAB1: a target of triptolide in macrophages. , 2014, Chemistry & biology.

[24]  Z. Miao,et al.  Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44 , 2016, Molecular Cancer Therapeutics.

[25]  Wei Tang,et al.  (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. , 2005, International immunopharmacology.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  J. A. Ross,et al.  PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. , 2003, Molecular cancer therapeutics.

[28]  A. Ganesan,et al.  Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. , 1999, Journal of the National Cancer Institute.

[29]  Z. Miao,et al.  Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. , 2012, Natural product reports.

[30]  Bin Zhang,et al.  Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[31]  J. Edwards,et al.  Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients , 2012, British Journal of Cancer.

[32]  Hu Xiaowen,et al.  Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation , 2012, Molecular Biology Reports.

[33]  S. Somlo,et al.  Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease , 2007, Proceedings of the National Academy of Sciences.

[34]  T. Uchiumi,et al.  Inhibition of RSK/YB‐1 signaling enhances the anti‐cancer effect of enzalutamide in prostate cancer , 2014, The Prostate.

[35]  M. Milowsky,et al.  Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance , 2015, Clinical pharmacology and therapeutics.

[36]  S. Gambhir,et al.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. , 2015, Cancer research.

[37]  M. Garcia-Blanco,et al.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. , 2014, Endocrine-related cancer.

[38]  V. Noé,et al.  Walnut polyphenol metabolites, urolithins A and B, inhibit the expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells. , 2014, Food & function.

[39]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[40]  J. Egly,et al.  The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process , 2011, The EMBO journal.

[41]  R. Andersen,et al.  Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain* , 2016, The Journal of Biological Chemistry.

[42]  M. Morris,et al.  Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer , 2016, Clinical Cancer Research.

[43]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[44]  Zhiyong Guo,et al.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy , 2014, Oncotarget.

[45]  E. Small,et al.  Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response , 2011, Clinical Cancer Research.

[46]  Z. Miao,et al.  Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents. , 2009, Journal of medicinal chemistry.

[47]  L. Stone.  Prostate cancer: Predicting resistance—AR-V7 is a potential biomarker , 2014, Nature Reviews Urology.

[48]  Bin Zhang,et al.  Triptolide Induces Growth Inhibition and Apoptosis of Human Laryngocarcinoma Cells by Enhancing p53 Activities and Suppressing E6-Mediated p53 Degradation , 2013, PloS one.

[49]  N. Vogelzang,et al.  Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[50]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[51]  Yanfei Gao,et al.  Proline-Directed Androgen Receptor Phosphorylation , 2013, Journal of molecular and genetic medicine : an international journal of biomedical research.

[52]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[53]  H. Mukhtar,et al.  Potent Anti-Proliferative, Pro-Apoptotic Activity of the Maytenus Royleanus Extract against Prostate Cancer Cells: Evidence in In-Vitro and In-Vivo Models , 2015, PloS one.

[54]  F. S. French,et al.  Site-specific Androgen Receptor Serine Phosphorylation Linked to Epidermal Growth Factor-dependent Growth of Castration-recurrent Prostate Cancer* , 2008, Journal of Biological Chemistry.

[55]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[56]  Martin E. Gleave,et al.  Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. , 2015, European urology.

[57]  Xueqi Fu,et al.  20(S)‐protopanaxadiol‐aglycone downregulation of the full‐length and splice variants of androgen receptor , 2013, International journal of cancer.

[58]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[59]  P. Marignani,et al.  Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells , 2009, Cancer biology & therapy.

[60]  S. Venz,et al.  Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer , 2016, Oncotarget.

[61]  Yingming Li,et al.  Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal* , 2012, The Journal of Biological Chemistry.

[62]  S. Logan,et al.  Mini-review: androgen receptor phosphorylation in prostate cancer. , 2013, American journal of clinical and experimental urology.

[63]  B. Dai,et al.  Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer , 2015, Scientific Reports.

[64]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.